BR112018000906A2 - ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto? - Google Patents
?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto?Info
- Publication number
- BR112018000906A2 BR112018000906A2 BR112018000906A BR112018000906A BR112018000906A2 BR 112018000906 A2 BR112018000906 A2 BR 112018000906A2 BR 112018000906 A BR112018000906 A BR 112018000906A BR 112018000906 A BR112018000906 A BR 112018000906A BR 112018000906 A2 BR112018000906 A2 BR 112018000906A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disease
- treatment
- prophylaxis
- mammal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Abstract
a presente invenção provê um composto heterocíclico tendo uma ação inibidora de hdac, e útil para o tratamento de doenças autoimunes e/ou doenças inflamatórias, doença de enxerto contra hospedeiro, cânceres, doenças do nervo central incluindo doenças neurodegenerativas, doença de charcot-marie-tooth e semelhantes, e uma composição farmacêutica compreendendo o composto. a presente invenção refere-se a um composto representado pela fórmula (i): em que cada símbolo é como definido na especificação ou um sal do mesmo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015143354 | 2015-07-17 | ||
JP2016029020 | 2016-02-18 | ||
PCT/JP2016/071655 WO2017014321A1 (en) | 2015-07-17 | 2016-07-15 | Oxadiazole derivatives useful as hdac inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018000906A2 true BR112018000906A2 (pt) | 2018-09-11 |
Family
ID=56853775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018000906A BR112018000906A2 (pt) | 2015-07-17 | 2016-07-15 | ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto? |
Country Status (11)
Country | Link |
---|---|
US (1) | US10308643B2 (pt) |
EP (1) | EP3325475B1 (pt) |
JP (1) | JP6671456B2 (pt) |
CN (1) | CN108026088B (pt) |
AU (1) | AU2016297362B2 (pt) |
BR (1) | BR112018000906A2 (pt) |
CA (1) | CA2992700A1 (pt) |
EA (1) | EA033198B1 (pt) |
ES (1) | ES2793014T3 (pt) |
TW (1) | TW201713649A (pt) |
WO (1) | WO2017014321A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3187497A4 (en) | 2014-08-26 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EA033198B1 (ru) | 2015-07-17 | 2019-09-30 | Такеда Фармасьютикал Компани Лимитед | Оксадиазольные производные, пригодные в качестве ингибиторов hdac |
JPWO2017014170A1 (ja) | 2015-07-17 | 2018-04-26 | 武田薬品工業株式会社 | 複素環化合物 |
JPWO2017033946A1 (ja) | 2015-08-25 | 2018-06-07 | 武田薬品工業株式会社 | 複素環化合物 |
WO2017110863A1 (ja) * | 2015-12-25 | 2017-06-29 | 住友化学株式会社 | オキサジアゾール化合物及びその用途 |
WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
CN111032651A (zh) * | 2017-07-31 | 2020-04-17 | 武田药品工业株式会社 | 杂环化合物 |
WO2019148005A1 (en) * | 2018-01-26 | 2019-08-01 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
BR112020016234A2 (pt) * | 2018-02-12 | 2020-12-15 | Bayer Aktiengesellschaft | Oxadiazóis fungicidas |
KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
CN113412259A (zh) | 2018-10-15 | 2021-09-17 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
CN111057069B (zh) * | 2018-10-16 | 2024-01-26 | 武汉光谷通用名药物研究院有限公司 | 一种环状化合物、其应用及组合物 |
CN109293567A (zh) * | 2018-11-23 | 2019-02-01 | 上海睿腾医药科技有限公司 | 一种5-溴-2-甲基烟酸乙酯的合成方法 |
WO2020158762A1 (ja) | 2019-01-30 | 2020-08-06 | 武田薬品工業株式会社 | 複素環化合物 |
JP2022526025A (ja) | 2019-04-09 | 2022-05-20 | ニューリックス セラピューティクス,インコーポレイテッド | Cbl-b阻害のための3-置換ピペリジン化合物、並びに癌ワクチン及び/又は腫瘍溶解性ウイルスと組み合わせたCbl-b阻害剤の使用 |
WO2020236654A1 (en) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
KR20220026581A (ko) | 2019-06-26 | 2022-03-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제를 위한 치환된 벤질-트리아졸 화합물, 및 이의 추가의 용도 |
CA3148769A1 (en) * | 2019-07-30 | 2021-02-04 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
CN110498759A (zh) * | 2019-09-12 | 2019-11-26 | 天津瑞岭化工有限公司 | 异吲哚啉酮类化合物的合成方法 |
TW202126643A (zh) | 2019-09-27 | 2021-07-16 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
EP4046688A4 (en) * | 2019-10-18 | 2023-09-27 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
MX2022006672A (es) | 2019-12-04 | 2022-08-08 | Nurix Therapeutics Inc | Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina. |
EP4192830A1 (en) * | 2020-08-07 | 2023-06-14 | Italfarmaco SpA | 2-(4-((5-(benzo[b]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (hdac6) for use in treating e.g. peripheral neuropathy |
CN111961020A (zh) * | 2020-08-31 | 2020-11-20 | 南通大学 | 一种四氢吡喃羧酸衍生物及其合成方法 |
WO2022129196A1 (en) | 2020-12-18 | 2022-06-23 | Bayer Aktiengesellschaft | Heterobicycle substituted 1,2,4-oxadiazoles as fungicides |
WO2023081328A1 (en) * | 2021-11-04 | 2023-05-11 | Valo Health, Inc. | Histone deacetylase 6 inhibitor compounds and uses thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
CA2626897A1 (en) | 2005-11-03 | 2007-05-18 | Joshua Close | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途 |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
JP2013517281A (ja) | 2010-01-13 | 2013-05-16 | テンペロ、ファーマシューティカルズ、インコーポレイテッド | 化合物及び方法 |
AU2011205283B2 (en) | 2010-01-13 | 2014-07-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
US9056843B2 (en) | 2011-07-08 | 2015-06-16 | Novartis Ag | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
WO2013009830A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
WO2013009827A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
KR101812237B1 (ko) | 2011-09-27 | 2017-12-27 | 코오롱인더스트리 주식회사 | 폴리에틸렌테레프탈레이트 연신사의 제조방법, 폴리에틸렌테레프탈레이트 연신사 및 타이어 코오드 |
WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
WO2013066831A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
MX2014006409A (es) | 2011-11-28 | 2014-07-30 | Novartis Ag | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. |
EP3187497A4 (en) | 2014-08-26 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2016039398A1 (ja) | 2014-09-09 | 2016-03-17 | 国立大学法人大阪大学 | 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 |
EA033198B1 (ru) | 2015-07-17 | 2019-09-30 | Такеда Фармасьютикал Компани Лимитед | Оксадиазольные производные, пригодные в качестве ингибиторов hdac |
JPWO2017014170A1 (ja) | 2015-07-17 | 2018-04-26 | 武田薬品工業株式会社 | 複素環化合物 |
JPWO2017033946A1 (ja) | 2015-08-25 | 2018-06-07 | 武田薬品工業株式会社 | 複素環化合物 |
WO2017110863A1 (ja) | 2015-12-25 | 2017-06-29 | 住友化学株式会社 | オキサジアゾール化合物及びその用途 |
WO2017222950A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
WO2017222952A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
-
2016
- 2016-07-15 EA EA201890338A patent/EA033198B1/ru not_active IP Right Cessation
- 2016-07-15 CA CA2992700A patent/CA2992700A1/en active Pending
- 2016-07-15 US US15/210,965 patent/US10308643B2/en active Active
- 2016-07-15 CN CN201680054153.1A patent/CN108026088B/zh active Active
- 2016-07-15 EP EP16760203.6A patent/EP3325475B1/en active Active
- 2016-07-15 JP JP2018502197A patent/JP6671456B2/ja active Active
- 2016-07-15 TW TW105122370A patent/TW201713649A/zh unknown
- 2016-07-15 WO PCT/JP2016/071655 patent/WO2017014321A1/en active Application Filing
- 2016-07-15 ES ES16760203T patent/ES2793014T3/es active Active
- 2016-07-15 AU AU2016297362A patent/AU2016297362B2/en not_active Ceased
- 2016-07-15 BR BR112018000906A patent/BR112018000906A2/pt active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
JP6671456B2 (ja) | 2020-03-25 |
WO2017014321A1 (en) | 2017-01-26 |
CA2992700A1 (en) | 2017-01-26 |
AU2016297362A1 (en) | 2018-02-22 |
ES2793014T3 (es) | 2020-11-12 |
CN108026088B (zh) | 2021-02-12 |
EP3325475B1 (en) | 2020-03-18 |
TW201713649A (zh) | 2017-04-16 |
US10308643B2 (en) | 2019-06-04 |
EP3325475A1 (en) | 2018-05-30 |
CN108026088A (zh) | 2018-05-11 |
AU2016297362B2 (en) | 2020-04-16 |
EA033198B1 (ru) | 2019-09-30 |
JP2018524378A (ja) | 2018-08-30 |
EA201890338A1 (ru) | 2018-07-31 |
US20170015655A1 (en) | 2017-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018000906A2 (pt) | ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto? | |
BR112019002576A2 (pt) | composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo | |
GEP20217316B (en) | Aromatic sulfonamide derivatives | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
BR112017027951A2 (pt) | composto inibitório de brk | |
BR112015019921A2 (pt) | composto inibidor de trk | |
BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
MX2016011037A (es) | Compuestos de fosfonato para el tratamiento de trastornos mediados por complemento. | |
BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
BR112012031580A2 (pt) | derivado de tetra-hidrocarbolina | |
BR112017002403A2 (pt) | formas de cristais de inibidores de glutaminase | |
BR112015030399B8 (pt) | Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3 | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
BR112015006738A2 (pt) | terapia de combinação usando belinostat e trabectedina | |
BR112018002547A2 (pt) | benzimidazóis substituídos, sua preparação e seu uso como produtos farmacêuticos | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
BR112016013754A2 (pt) | Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma | |
BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |